End-of-day quote
Shenzhen S.E.
06:00:00 2024-05-13 pm EDT
|
5-day change
|
1st Jan Change
|
33
CNY
|
+2.10%
|
|
-2.88%
|
-7.98%
|
Fiscal Period: December |
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
15,911
|
12,518
|
18,830
|
17,345
|
-
|
-
|
Enterprise Value (EV)
1 |
15,911
|
12,518
|
18,830
|
17,345
|
17,345
|
17,345
|
P/E ratio
|
35.6
x
|
24.8
x
|
29.2
x
|
20.5
x
|
15.6
x
|
13.1
x
|
Yield
|
-
|
-
|
2.12%
|
-
|
2.17%
|
-
|
Capitalization / Revenue
|
2.26
x
|
1.67
x
|
2.49
x
|
2.01
x
|
1.68
x
|
1.47
x
|
EV / Revenue
|
2.26
x
|
1.67
x
|
2.49
x
|
2.01
x
|
1.68
x
|
1.47
x
|
EV / EBITDA
|
25.8
x
|
17.8
x
|
19.9
x
|
14
x
|
10.5
x
|
9.08
x
|
EV / FCF
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
Price to Book
|
7.38
x
|
-
|
7.34
x
|
5.16
x
|
4.48
x
|
3.18
x
|
Nbr of stocks (in thousands)
|
525,100
|
525,100
|
525,100
|
525,613
|
-
|
-
|
Reference price
2 |
30.30
|
23.84
|
35.86
|
33.00
|
33.00
|
33.00
|
Announcement Date
|
4/25/22
|
4/24/23
|
4/22/24
|
-
|
-
|
-
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
-
|
7,052
|
7,510
|
7,564
|
8,643
|
10,300
|
11,775
|
EBITDA
1 |
-
|
617
|
704.3
|
948.5
|
1,236
|
1,652
|
1,911
|
EBIT
1 |
-
|
563.9
|
674.3
|
888.1
|
1,143
|
1,517
|
1,776
|
Operating Margin
|
-
|
8%
|
8.98%
|
11.74%
|
13.22%
|
14.73%
|
15.08%
|
Earnings before Tax (EBT)
1 |
-
|
567.9
|
668.5
|
873.6
|
1,135
|
1,509
|
1,767
|
Net income
1 |
272.7
|
422.8
|
502.1
|
656.3
|
847.4
|
1,112
|
1,319
|
Net margin
|
-
|
6%
|
6.69%
|
8.68%
|
9.8%
|
10.8%
|
11.21%
|
EPS
2 |
0.5800
|
0.8500
|
0.9600
|
1.230
|
1.613
|
2.116
|
2.510
|
Free Cash Flow
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
2 |
-
|
-
|
-
|
0.7620
|
-
|
0.7150
|
-
|
Announcement Date
|
6/23/21
|
4/25/22
|
4/24/23
|
4/22/24
|
-
|
-
|
-
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
ROE (net income / shareholders' equity)
|
-
|
22.9%
|
22.8%
|
27.3%
|
25.3%
|
29.6%
|
24.5%
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
11.4%
|
15.7%
|
13.3%
|
Assets
1 |
-
|
-
|
-
|
-
|
7,433
|
7,107
|
9,921
|
Book Value Per Share
2 |
-
|
4.110
|
-
|
4.890
|
6.400
|
7.360
|
10.40
|
Cash Flow per Share
2 |
-
|
0.3500
|
0.5800
|
1.160
|
1.310
|
1.470
|
1.850
|
Capex
1 |
-
|
25.5
|
104
|
123
|
217
|
216
|
216
|
Capex / Sales
|
-
|
0.36%
|
1.39%
|
1.63%
|
2.51%
|
2.1%
|
1.83%
|
Announcement Date
|
6/23/21
|
4/25/22
|
4/24/23
|
4/22/24
|
-
|
-
|
-
|
Average target price
48
CNY Spread / Average Target +45.45% Consensus |
1st Jan change
|
Capi.
|
---|
| -7.98% | 2.35B | | +19.14% | 72.09B | | -3.34% | 23.88B | | +10.27% | 8.89B | | +12.67% | 8.46B | | -17.41% | 8.29B | | +9.65% | 4.9B | | +21.40% | 4.34B | | -1.41% | 3.98B | | -1.99% | 3.89B |
Pharmaceuticals Wholesale
|